Daily BriefsUnited States

Daily Brief United States: Digital Realty Trust, Copper, OpGen and more

In today’s briefing:

  • Digital Realty Trust: A Dividend Growth Investor’s Pal
  • Commodity Watch – A rebound in the most cyclical asset class?
  • OpGen – Feasibility milestone from FIND collaboration


Digital Realty Trust: A Dividend Growth Investor’s Pal

By Pearl Gray Equity and Research

  • Digital Realty Trust, Inc. is executing a phenomenal strategy, with additional pipeline developments coming online soon.
  • Digital Realty is faced with cyclical valuation concerns, we think they will be short-lived.
  • Digital Realty Trust, Inc. (NYSE:DLR) presents an interesting talking point

Commodity Watch – A rebound in the most cyclical asset class?

By Andreas Steno

  • Welcome to the final series of our “Business Cycle Week”, where we cover how a possible rebound in manufacturing might affect asset markets, and if markets are already starting to position for it.
  • Commodities is the only asset class we need to tick off, and what a way to end the business cycle week with the most cyclical asset of them all, looking to benefit the most from a rebound in manufacturing.
  • Commodities have had a rough 2022 (and start of 2023) as USD strength and a lack of Chinese demand have held commodities prices down, despite the scarcity that characterizes the market currently.

OpGen – Feasibility milestone from FIND collaboration

By Edison Investment Research

OpGen has announced that Curetis (its German subsidiary) has met its objectives agreed under its extended R&D collaboration with FIND (a global non-profit alliance for diagnostics), triggering a $0.2m milestone payment to OpGen. Under the expanded scope of the feasibility study for the Unyvero A30 RQ platform, OpGen was required to provide three more deliverables: an antimicrobial stewardship module, a ‘data everywhere’ concept and next-generation sequencing (NGS) strain analysis. While successful completion of the feasibility stage supports Unyvero A30’s applicability in low-to-middle income countries (LMICs), it also paves the way for a subsequent R&D agreement with FIND in developing LMIC-specific Unyvero A30 antimicrobial resistance (AMR) solutions. We await further details from management on the next potential steps of the collaboration.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars